G. Walker

Androgen receptor antigen density and S-phase fraction in prostate cancer: a pilot study

A. Markoe, C. Milikowski, A. Krishan, 2003, Prostate Cancer and Prostatic Diseases.

Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.

P. Fasching, F. Couch, K. Gelmon, 2021, European journal of cancer.

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study

J. O’Shaughnessy, M. Cazzaniga, S. Ohsumi, 2020, Breast Cancer Research.

Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study

E. Fukuma, Masato Takahashi, K. Jung, 2021, Breast Cancer.

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study

J. O’Shaughnessy, M. Cazzaniga, S. Ohsumi, 2020, Breast cancer research : BCR.

335TiP Open-label, multinational, multicenter, phase IIIb/IV study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer (HER2+ BC): DESTINY-Breast12

V. Müller, G. Jerusalem, N. Niikura, 2021, Annals of Oncology.

CLRM-14. OPEN-LABEL, MULTINATIONAL, MULTICENTER, PHASE 3B/4 STUDY OF TRASTUZUMAB DERUXTECAN (T-DXD) IN PATIENTS WITH OR WITHOUT BASELINE BRAIN METASTASIS (BM) WITH PREVIOUSLY TREATED ADVANCED/METASTATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE BREAST CANCER (HER2+ BC): DESTINY-BREAST12

N. Lin, G. Viale, N. Harbeck, 2021, Neuro-Oncology Advances.